- Q1 Results 1) Gland Pharma Ltd on Tuesday (August 5) reported a 49.9% spike in net profit at ₹215.4 crore for the first quarter of FY26, up from ₹143.7 crore in the year-ago quarter. 2) Revenue from operations increased 7.4% to ₹1,505.6 crore against ₹1,401.7 crore in Q1FY25. 3) At the operating level, EBITDA jumped 39% to ₹367.6 crore in the April-June quarter over ₹264.5 crore last year. The EBITDA expanded significantly to 24.4% versus 19% year-on-year. 4) R&D expenses & new drugs The company reported total R&D expenses of ₹46 crore in Q1FY26, representing 4.4% of its revenue. During the quarter, the company launched 12 new molecules in regulated markets, including colistimethate, epinephrine, vancomycin (three new strengths), liraglutide, and acetaminophen bags. 5) Gland Pharma is also progressing on its co-development partnerships, with 15 products in development — seven under the 505(b)(2) pathway and eight as ANDAs. Commercialisation of these is expected to begin in FY28. Additionally, the company filed one ready-to-use (RTU) infusion bag product in the quarter, bringing the total number filed in the USA to 20, of which 14 have been approved. Ten more RTU products are under development, targeting a market size of approximately $767 6) Results are better then expectations. 7) All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24

#StockInNews#FundamentalViews

592 likes·57 comments